



11960 Southwest 144th Street
Miami, Florida 33186
305-253-1916 ▼ Toll-Free: 888-253-5099
www.noven.com

PRESS RELEASE

NOVEN ANNOUNCES POSITIVE PHASE 2 RESULTS OF INVESTIGATIONAL d-AMPHETAMINE TRANSDERMAL SYSTEM FOR ADHD

July 22, 2013 – Miami, FL and New York, NY – Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced top-line results from its Phase 2 clinical study evaluating d-Amphetamine Transdermal System (d-ATS) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents. Currently, there is no amphetamine-based transdermal treatment option available for ADHD.

The Phase 2 study was a randomized, double-blind, placebo-controlled, crossover, laboratory classroom study to evaluate the safety and efficacy of d-ATS compared to placebo in subjects 6 to 17 years of age. The 7-week study enrolled 110 patients.

The primary outcome measure in the study was mean total SKAMP score for d-ATS compared to placebo. The SKAMP scale measures manifestations of ADHD symptoms using an independent observer (teacher) rating of the child's impairment in classroom behavior. The Phase 2 study achieved the primary endpoint with statistical significance, and no serious adverse events were reported.

Joel S. Lippman, M.D., Noven's Executive Vice President & Chief Medical Officer, said: "We are pleased with the results of our d-ATS Phase 2 study, and are preparing to advance the program into Phase 3 development."

About Noven

Noven Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development, manufacturing, marketing and sale of prescription pharmaceutical products. Noven is committed to developing and offering products and technologies that meaningfully benefit patients, its customers and its industry partners. Noven is a stand-alone operating subsidiary of Japan-based Hisamitsu Pharmaceutical Co., Inc., and serves as Hisamitsu's U.S. growth platform in prescription pharmaceuticals. For more information about Noven, visit www.noven.com. For information about Hisamitsu, visit www.hisamitsu.co.jp/english.

Contacts

Joseph C. Jones
Vice President – Corporate Affairs
Noven Pharmaceuticals, Inc.
corporateaffairs@noven.com
305-253-1916